Technology Evaluation: Mepolizumab, GlaxoSmithKline

Overview

Journal Curr Opin Mol Ther

Specialties Molecular Biology
Pharmacology

Date 2003 Jul 23

PMID 12870444

Citations 8

Authors

Gnanasegaram Gnanakumaran

K Suresh Babu

Affiliations

Soon will be listed here.

Abstract

GlaxoSmithKline (formerly SmithKline Beecham) is developing mepolizumab (SB-240563), a monoclonal antibody directed against IL-5, as a potential treatment for asthma and atopic dermatitis. Phase II trials in asthma were underway by April 1998 and by March 2002, phase II trials had also been initiated in atopic dermatitis.

Citing Articles

Monoclonal Antibodies and Airway Diseases.

Lyly A, Laulajainen-Hongisto A, Gevaert P, Kauppi P, Toppila-Salmi S Int J Mol Sci. 2020; 21(24).

PMID: 33322143 PMC: 7763928. DOI: 10.3390/ijms21249477.

Real-life experience with benralizumab during 6 months.

Padilla-Galo A, Levy-Abitbol R, Olveira C, Valencia Azcona B, Perez Morales M, Rivas-Ruiz F BMC Pulm Med. 2020; 20(1):184.

PMID: 32600318 PMC: 7325276. DOI: 10.1186/s12890-020-01220-9.

Interleukin-5 in the Pathophysiology of Severe Asthma.

Pelaia C, Paoletti G, Puggioni F, Racca F, Pelaia G, Canonica G Front Physiol. 2020; 10:1514.

PMID: 31920718 PMC: 6927944. DOI: 10.3389/fphys.2019.01514.

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.

Emma R, Morjaria J, Fuochi V, Polosa R, Caruso M Ther Adv Respir Dis. 2018; 12:1753466618808490.

PMID: 30354852 PMC: 6204623. DOI: 10.1177/1753466618808490.

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.

Pelaia C, Vatrella A, Busceti M, Gallelli L, Terracciano R, Savino R Drug Des Devel Ther. 2017; 11:3137-3144.

PMID: 29133975 PMC: 5669784. DOI: 10.2147/DDDT.S150656.